Reimbursed Care Access in Central African Republic

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. At the international level, psilocybin is included among classical psychedelics controlled by the 1971 UN Convention on Psychotropic Substances, which CAR has ratified, and that international scheduling informs most national prohibitions. # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. MDMA is scheduled under the 1971 UN Convention on Psychotropic Substances and that international control is reflected in CAR’s obligations as a State Party. # #

There is no public evidence of a national regulatory approval, reimbursement pathway, or routine clinical provision of intranasal esketamine (Spravato®) in the Central African Republic; esketamine products are prescription/marketed medicines in higher‑income jurisdictions only when authorized by national regulators, and their presence in CAR would require specific national marketing authorization and procurement channels that are not documented in publicly available CAR national lists. Ketamine — the racemic compound — is on the WHO Model List of Essential Medicines as an injectable anesthetic and is used in many low‑resource African settings for anesthesia and emergency care, which explains clinical availability of racemic ketamine but does not imply esketamine approval or reimbursement. # #

Ketamine (racemic) is recognized internationally as an essential anesthetic and is included on the World Health Organization’s Model List of Essential Medicines for use as an injectable anesthetic; this listing strongly supports its clinical availability in low‑resource and humanitarian settings, including in sub‑Saharan African countries where formal anesthesia capacity exists. #

In the Central African Republic specifically, there is no publicly available national reimbursement scheme or specialty psychiatric program documented for ketamine as an antidepressant or for psychedelic‑assisted therapy; instead, ketamine’s primary documented role in CAR and comparable settings is as an essential anesthetic/analgesic in hospitals and emergency care. Procurement and use typically occur through hospital budgets, donor procurement, or ministry of health supply chains rather than through a national, reimbursed mental‑health treatment pathway. The WHO EML status provides the global basis for hospital procurement, but it does not create reimbursement entitlements for psychiatric indications in CAR. #

Regulatory/insurance nuance: CAR is a low‑resource context with fragmented public financing for health; there is no evidence that public or national social insurance programs in CAR reimburse off‑label ketamine for psychiatric indications (e.g., treatment‑resistant depression). Where ketamine is used for mental‑health indications in low‑ and middle‑income countries it is commonly delivered through private clinics or research programs and paid out‑of‑pocket or via project funding rather than through public reimbursement — the same situation should be assumed for CAR in the absence of contrary national policy documents. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. DMT is explicitly controlled under the 1971 UN Convention on Psychotropic Substances and CAR is a State Party to relevant international drug control instruments that underpin domestic prohibition. Note that traditional brews containing DMT (e.g., ayahuasca) occupy legal ambiguity in some jurisdictions, but that ambiguity stems from plant‑material vs. pure‑compound distinctions; CAR’s treaty obligations do not provide for medical access outside approved research. # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. 5‑MeO‑DMT is treated as a controlled tryptamine in many national systems informed by UN scheduling, and there is no documented clinical/reimbursement pathway in CAR. # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. While ibogaine has cultural roots in parts of Central Africa (notably Gabon), its psychoactive alkaloid is subject to strict controls in most states and there is no documented, regulated medical/ reimbursed use in CAR. # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Although ayahuasca as a brew contains plant materials and international scheduling targets constituent DMT rather than the plants themselves, CAR’s obligations under UN drug control conventions and common national implementations mean there is no recognized, reimbursed medical pathway for ayahuasca in CAR. Use would, at minimum, be legally risky and limited to approved scientific research if permitted. # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Mescaline (and mescaline‑containing cacti) are controlled substances under the UN psychotropic framework; CAR’s treaty commitments and common domestic implementations mean no authorized, reimbursed medical use in CAR. # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. The 2C family (2C‑B, 2C‑I, 2C‑X variants) are typically controlled under national psychotropic/analog laws informed by the 1971 Convention; there is no evidence of medical/reimbursed access in CAR. # #